Animal model of systemic sclerosis

Journal of Dermatology

Volumn 37, Issue 1, 2010, Pages 26-41

  Yamamoto, Toshiyuki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bleomycin; Cytokine; Mouse model; Scleroderma

Indexed keywords

BLEOMYCIN; CHEMOKINE; CYTOKINE; DASATINIB; GAMMA INTERFERON; GROWTH FACTOR; HALOFUGINONE; IMATINIB; NILOTINIB; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

BLOOD VESSEL INJURY; COMPLEX FORMATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; FIBROBLAST; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE; MACROPHAGE; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

ANIMALS; CHICKENS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; RELAXIN; SCLERODERMA, SYSTEMIC;

EID: 75649110070     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00764.x     Document Type: Review

References (148)

1. Yamamoto T. Scleroderma-pathophysiology. Eur J Dermatol 2009 19: 14 24.
2. Yamamoto T. Bleomycin and the skin. Br J Dermatol 2006 155: 869 875.
3. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006 297: 333 344.
4. Clark JC, Starcher BC, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung skin fibroblasts in culture. Biochim Biophys Acta 1980 631: 359 370.
5. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin gene expression in human skin fibroblasts. Arch Dermatol Res 2000 292: 556 561.
6. Breen E, Shull S, Burne S et al. Bleomycin regulation of transforming growth factor-β mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 1992 6: 146 152.
7. King SL, Lichtler AC, Rowe DW et al. Bleomycin stimulates proα1(I) collagen promoter through transforming growth factor-β response element by intracellular and extracellular signaling. J Biol Chem 1994 269: 13156 13161.
8. Phan SH, Gharaee-Kermani M, Wolber F, Ryan US. Stimulation of rat endothelial cell transforming growth factor-β production by bleomycin. J Clin Invest 1991 87: 148 154.
9. Mountz JD, Downs Minor MB, Turner R, Thomas MB, Richards F, Pisko E. Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983 108: 679 686.
10. Yamamoto T, Takagawa S, Katayama I et al. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999 112: 456 462.
11. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II: bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/Wv mice. J Rheumatol 1999 26: 2628 2634.
12. Yamamoto T, Kuroda M, Takagawa S, Nishioka K. Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000 292: 535 541.
13. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001 117: 999 1001.
14. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002 102: 77 83.
15. Yamamoto T, Nishioka K. Animal model of sclerotic skin. VI: evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004 295: 453 456.
16. Ishikawa H, Takeda K, Okamoto A, Matsuo SI, Isobe KI. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4(+) T cells. J Invest Dermatol 2009 129: 1688 1695.
17. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-β1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J Med Dent Sci 2004 51: 7 17.
18. Shibusawa Y, Negishi I, Tabata Y, Ishikawa O. Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(l-lactic acid) microspheres. Rheumatology 2008 47: 454 457.
19. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990 86: 917 922.
20. Matsushita M, Yamamoto T, Nishioka K. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 2005 139: 429 438.
21. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002 99: 3908 3913.
22. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004 113: 253 264.
23. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003 48: 1964 1978.
24. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J. Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003 121: 41 50.
25. Lakos G, Takagawa S, Chen SJ et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004 165: 203 217.
26. Ihn H, Yamane K, Tamaki K. Increased phosphorylaton and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol 2005 125: 247 255.
27. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004 172: 7123 7135.
28. Bhattacharyya S, Chen SJ, Wu M et al. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008 173: 1085 1099.
29. Skhirtladze C, Distler O, Dees C et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008 58: 1475 1484.
30. Liu S, Kapoor M, Shi-wen X et al. Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice. Arthritis Rheum 2008 58: 2189 2195.
31. Makhluf HA, Stepniakowska J, Hoffman S, Smith E, LeRoy EC, Trojanowska M. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996 107: 856 859.
32. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992 90: 1479 1485.
33. Elovic AE, Ohyama H, Sauty A et al. IL-4-dependent regulation of TGF-alpha and TGF-beta1 expression in human eosinophils. J Immunol 1998 160: 6121 6127.
34. Seder RA, Marth T, Sieve MC et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposite effects, while TGF-beta positively regulates its own production. J Immunol 1998 160: 5719 5728.
35. Needlemann BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1985 28: 775 780.
36. Serpier H, Gillery P, Salmon-Ehr V et al. Antagonistic effect of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997 109: 158 162.
37. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of anti-transforming growth factor-β antibody in bleomycin-induced scleroderma. Clin Immunol 1999 92: 6 13.
38. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 2004 135: 348 356.
39. Lakos G, Melichian D, Wu M, Varga J. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006 73: 224 237.
40. Aliprantis AO, Wang J, Fathman JW et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007 104: 2827 2830.
41. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998 101: 2129 2139.
42. Jinnin M, Ihn H, Yamane K, Tamaki K. Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004 279: 41783 41791.
43. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000 292: 988 994.
44. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998 10: 1421 1433.
45. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 2001 194: 809 821.
46. Belperio JA, Dy M, Burdick MD et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002 27: 419 427.
47. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006 140: 345 356.
48. Yamamoto T. Pathogenic role of CCL2/MCP-1 in scleroderma. Front Biosci 2008 13: 2686 2695.
49. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996 271: 17779 17784.
50. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1α loop. J Immunol 2000 164: 6174 6179.
51. Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects of monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001 44: 2665 2678.
52. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001 44: 1382 1386.
53. Hasegawa M, Sato S, Takehara K. Augmentation of production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999 117: 159 165.
54. Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001 31: 2936 2941. (Pubitemid 32994545)
55. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001 26: 133 139. (Pubitemid 32510721)
56. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999 103: 1253 1260.
57. Zhu Z, Ma B, Zheng T et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002 168: 2953 2962.
58. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003 121: 510 516.
59. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006 126: 1900 1908.
60. Galindo M, Santiago B, Alcami J, Riyero M, Martin-Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001 123: 36 41.
61. Hebbar M, Gillot JM, Hachulla E et al. Early expression of E-selectin, tumor necrosis factorα, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996 39: 1161 1165.
62. Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumor necrosis factor α serological levels in localized and systemic sclerosis. Rom J Intern Med 1998 36: 251 259.
63. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997 24: 663 665.
64. Distler JHW, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor α in fibrotic diseases. Arthritis Rheum 2008 58: 2228 2235.
65. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992 18: 29 43.
66. Piguet PF, Collart MA, Gran GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989 170: 655 663.
67. Ortiz LA, Lasky J, Lungarella G et al. Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999 20: 825 833.
68. Murota H, Hamasaki Y, Nakashima T, Yamamoto K, Katayama I, Matsuyama T. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum 2003 48: 1117 1125.
69. Laplante P, Raymond M-A, Gagnon G et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005 174: 5740 5749.
70. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000 43: 2230 2239.
71. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001 44: 1667 1676.
72. Sgonc R, Dietrich H, Sieberer C, Wick G, Christner PJ, Jimenez SA. Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 1999 42: 581 584.
73. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004 122: 44 50.
74. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis. Expanded naïve B cells and diminished but activated memory B cells. Arthritis Rheum 2001 50: 918 927.
75. Yoshizaki A, Iwata Y, Mokura K et al. CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008 172: 1650 1663.
76. Santiago B, Gutierrez-Canas I, Dotor J et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005 125: 450 455.
77. Yokozeki M, Baba Y, Shimokawa H, Moriyama K, Kuroda T. Interferon-γ inhibits the myofibroblastic phenotype of rat palatal fibroblasts induced by transforming growth factor-β1 in vitro. FEBS Lett 1999 442: 61 64.
78. Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-β/SMAD signaling by the interferon-γ/STAT pathway. Nature 1999 397: 710 713.
79. Yamamoto T, Takagawa S, Kuroda M, Nishioka K. Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000 292: 362 365.
80. Kimura M, Kawahito Y, Hamaguchi M et al. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced sin sclerosis in mice. Biomed Pharmacother 2007 61: 222 228.
81. Yamamoto T, Takagawa S, Mizushima Y, Nishioka K. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999 113: 843 847.
82. Yamamoto T, Nishioka K. Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology 2002 41: 594 596.
83. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001 59: 2023 2038. (Pubitemid 32467594)
84. Wu M-H, Yokozeki H, Takagawa S et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004 11: 170 180.
85. Chan ES, Fernandez P, Merchant AA et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006 54: 2632 2642.
86. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004 50: 1305 1318.
87. Burgess H, Daugherty L, Thatcher T et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol 2005 288: L1146 L1153.
88. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ. Am J Pathol 2009 174: 519 533.
89. Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007 56: 311 322.
90. Akhmetshina A, Venalis P, Dees C et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009 60: 219 224.
91. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008 22: 2214 2222.
92. Fukasawa C, Kawaguchi Y, Harigai M et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003 33: 2792 2800.
93. Kawai M, Masuda A, Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008 58: 3562 3573.
94. Kokot A, Sindrilaru A, Schiller M et al. α-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma. Arthritis Rheum 2009 60: 592 603.
95. Kasturi KN, Shibata S, Muryoi T, Bona C. Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol 1994 11: 253 271.
96. Pablos JL, Everett ET, Harley R, LeRoy EC, Norris JS. Transforming growth factor-β1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995 72: 180 185.
97. Philips N, Bashey RI, Jimenez SA. Increased α1(I) procollagen gene expression in tight skin (Tsk) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor. J Biol Chem 1995 270: 9313 9321.
98. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008 128: 871 881.
99. Wang HW, Tedla N, Hunt JE, Wakefield D, McNeil HP. Mast cell accumulaton and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005 14: 295 302.
100. Walker M, Harley R, LeRoy EC. Inhibition of fibrosis in Tsk mice by blocking mast cell degranulation. J Rheumatol 1987 14: 299 301.
101. Kikuchi H, Hanazawa S, Takeshita A, Nakada Y, Yamashita Y, Kitano S. Interleukin-4 acts as a potent stimulator for expression of monocyte chemoattractant JE/MCP-1 in mouse peritoneal macrophages. Biochem Biophys Res Commun 1993 203: 562 569.
102. Lee YW, Hennig B, Toborek M. Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 2003 284: H185 H192.
103. Lukacs NW, Chensue SW, Karpus WJ et al. C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am J Pathol 1997 150: 1861 1868.
104. Baxter RM, Crowell TP, McCrann ME, Frew EM, Gardner H. Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest 2005 85: 1199 1209.
105. MacGaha TL, Saito S, Phelps RG et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Rα and transforming growth factor β genes. J Invest Dermatol 2001 116: 136 143.
106. MacGaha TL, Le M, Kodera T et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 2003 48: 2275 2284.
107. Ong CJ, Ip S, The SJ et al. A role for T helper 2 cells in mediating skin fibroblasts in tight-skin mice. Cell Immunol 1999 196: 60 68.
108. MacGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I-collagen synthesis and skin sclerosis, blocks transforming growth factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002 118: 461 470.
109. Ong VH, Evans LA, Shiwen X et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003 48: 1979 1991.
110. Wallace VA, Kondo S, Kono T et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994 24: 1463 1466.
111. Saito E, Fujimoto M, Hasegawa M et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight skin mice. J Clin Invest 2002 109: 1453 1462.
112. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006 169: 954 966.
113. Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mouse 1. J Invest Dermatol 2002 119: 1379 1387.
114. Dooley A, Low SY, Holmes A et al. Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis. Rheumatology 2008 47: 272 280.
115. Ong D, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998 128: 2619 2629.
116. Shen Y, Ichino M, Nakazawa M, Minami M. CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol 2005 124: 1141 1148.
117. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002 46: 1689 1690.
118. Shiota N, Kakizoe E, Shimoura K, Tanaka T, Okunishi H. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol 2005 145: 424 431.
119. Granot I, Halevy O, Hurwitz S, Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1993 1156: 107 112.
120. Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intima hyperplasia. Arch Surg 1995 130: 257 261.
121. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 1996 106: 84 88. (Pubitemid 26053386)
122. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- β-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002 118: 461 470.
123. Pines M, Domb A, Ohara M et al. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol 2001 62: 1221 1227.
124. Komura K, Fujimoto M, Yanaba K et al. Blockade of CD40/CD40 ligand interaction attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008 67: 867 872.
125. Iwasaki T, Imado T, Kitano S, Sano H. Hepatocyte growth factor ameliorates dermal sclerosis in the tight-skin mouse model of scleroderma. Arthritis Res Ther 2006 8: R161.
126. Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The tight skin 2 mouse: an animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 1995 38: 1791 1798.
127. Christner PJ, Yufit Y, Peters J, MacGrath R, Jimenez SA. Transcriptional activation of the α1(I) procollagen gene and upregulation of α1(I) and α1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis Rheum 1998 41: 2132 2142.
128. Christner PJ, Yufit Y, Peters J, MacGrath R, Conway RF, Jimenez SA. Transcriptional activation of α1(III) procollagen gene in Tsk2/+ dermal fibroblasts. Biochem Biophys Res Commun 2003 303: 406 412.
129. Barisic-Dujmovic T, Boban I, Clark SH. Regulation of collagen gene expression in the Tsk2 mouse. J Cell Physiol 2008 215: 464 471.
130. Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, Christner PJ. Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol 2005 175: 2418 2426.
131. Mccormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999 163: 5693 5699.
132. Zhang Y, Mccormick LL, Desai SR, Wu S, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002 168: 3088 3098.
133. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007 127: 281 292.
134. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versus-host induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004 50: 1319 1331.
135. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003 121: 713 719.
136. Shinozaki M, Kawara S, Hayashi N, Kakinuma T, Igarashi A, Takehara K. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor-beta-simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997 237: 292 297.
137. Mori T, Kawara S, Shinozaki M et al. Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis. A mouse fibrosis model. J Cell Physiol 1999 181: 153 159.
138. Takehara K. Pathogenesis of systemic sclerosis. J Rheumatol 2003 30: 755 759.
139. Chujo S, Shirasaki F, Kawara S et al. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2005 203: 447 456.
140. Ikawa Y, Ng PS, Endo K et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol 2008 216: 680 687.
141. Chujo S, Shirasaki F, Kondo-Mitazaki M, Ikawa Y, Takehara K. Role of connective tissue growth factor and its interation with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol 2009 220: 189 195.
142. Van De Water J, Gershwin ME. Avian scleroderma. An inherited fibrotic disease of White Leghorn chickens resembling progressive systemic sclerosis. Am J Pathol 1986 120: 478 482.
143. Gruschwitz MS, Moormann S, Kromer G et al. Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1991 4: 577 593.
144. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000 43: 2550 2562.
145. Worda M, Sgonc R, Dietrich H et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003 48: 2605 2614.
146. Denton CP, Zheng B, Evans LA et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003 278: 25109 25119.
147. Denton CP, Lindahl GE, Khan K et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIk). J Biol Chem 2005 280: 16053 16065.
148. Samuel CS, Zhao C, Yang Q et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005 125: 692 699.